Lorraine Levitt Katz1, Barbara J Anderson2,3, Siripoom V McKay2, Roberto Izquierdo4, Terri L Casey5, Laurie A Higgins6, Aimee Wauters7, Kathryn Hirst8, Kristen J Nadeau9. 1. Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, and Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 2. Baylor College of Medicine, Houston, TX. 3. Texas Children's Hospital, Houston, TX. 4. State University of New York Upstate Medical University, Syracuse, NY. 5. University Hospitals Case Medical Center, Cleveland, OH. 6. Pediatric, Adolescent and Young Adult Section, Joslin Diabetes Center, Boston, MA. 7. University of Texas Health Science Center, San Antonio, TX. 8. George Washington University Biostatistics Center, Rockville, MD khirst@bsc.gwu.edu. 9. University of Colorado Anschutz Medical Campus, Aurora, CO.
Abstract
OBJECTIVE: To identify factors that predict medication adherence and to examine relationships among adherence, glycemic control, and indices of insulin action in TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth). RESEARCH DESIGN AND METHODS: A total of 699 youth 10-17 years old with recent-onset type 2 diabetes and ≥80% adherence to metformin therapy for ≥8 weeks during a run-in period were randomized to receive one of three treatments. Participants took two study pills twice daily. Adherence was calculated by pill count from blister packs returned at visits. High adherence was defined as taking ≥80% of medication; low adherence was defined as taking <80% of medication. Depressive symptoms, insulin sensitivity (1/fasting insulin), insulinogenic index, and oral disposition index (oDI) were measured. Survival analysis examined the relationship between medication adherence and loss of glycemic control. Generalized linear mixed models analyzed trends in adherence over time. RESULTS: In this low socioeconomic cohort, high and low adherence did not differ by sex, age, family income, parental education, or treatment group. Adherence declined over time (72% high adherence at 2 months, 56% adherence at 48 months, P < 0.0001). A greater percentage of participants with low adherence had clinically significant depressive symptoms at baseline (18% vs. 12%, P = 0.0415). No adherence threshold predicted the loss of glycemic control. Longitudinally, participants with high adherence had significantly greater insulin sensitivity and oDI than those with low adherence. CONCLUSIONS: In the cohort, the presence of baseline clinically significant depressive symptoms was associated with subsequent lower adherence. Medication adherence was positively associated with insulin sensitivity and oDI, but, because of disease progression, adherence did not predict long-term treatment success.
RCT Entities:
OBJECTIVE: To identify factors that predict medication adherence and to examine relationships among adherence, glycemic control, and indices of insulin action in TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth). RESEARCH DESIGN AND METHODS: A total of 699 youth 10-17 years old with recent-onset type 2 diabetes and ≥80% adherence to metformin therapy for ≥8 weeks during a run-in period were randomized to receive one of three treatments. Participants took two study pills twice daily. Adherence was calculated by pill count from blister packs returned at visits. High adherence was defined as taking ≥80% of medication; low adherence was defined as taking <80% of medication. Depressive symptoms, insulin sensitivity (1/fasting insulin), insulinogenic index, and oral disposition index (oDI) were measured. Survival analysis examined the relationship between medication adherence and loss of glycemic control. Generalized linear mixed models analyzed trends in adherence over time. RESULTS: In this low socioeconomic cohort, high and low adherence did not differ by sex, age, family income, parental education, or treatment group. Adherence declined over time (72% high adherence at 2 months, 56% adherence at 48 months, P < 0.0001). A greater percentage of participants with low adherence had clinically significant depressive symptoms at baseline (18% vs. 12%, P = 0.0415). No adherence threshold predicted the loss of glycemic control. Longitudinally, participants with high adherence had significantly greater insulin sensitivity and oDI than those with low adherence. CONCLUSIONS: In the cohort, the presence of baseline clinically significant depressive symptoms was associated with subsequent lower adherence. Medication adherence was positively associated with insulin sensitivity and oDI, but, because of disease progression, adherence did not predict long-term treatment success.
Authors: Denise E Wilfley; Tiffany L Tibbs; Dorothy J Van Buren; Kelle P Reach; Mark S Walker; Leonard H Epstein Journal: Health Psychol Date: 2007-09 Impact factor: 4.267
Authors: Elizabeth A Walker; Mark Molitch; M Kaye Kramer; Steven Kahn; Yong Ma; Sharon Edelstein; Kellie Smith; Mariana Kiefer Johnson; Abbas Kitabchi; Jill Crandall Journal: Diabetes Care Date: 2006-09 Impact factor: 19.112
Authors: Meda E Pavkov; Peter H Bennett; William C Knowler; Jonathan Krakoff; Maurice L Sievers; Robert G Nelson Journal: JAMA Date: 2006-07-26 Impact factor: 56.272
Authors: Kellee M Miller; Roy W Beck; Richard M Bergenstal; Robin S Goland; Michael J Haller; Janet B McGill; Henry Rodriguez; Jill H Simmons; Irl B Hirsch Journal: Diabetes Care Date: 2013-02-01 Impact factor: 19.112
Authors: Maria I Constantino; Lynda Molyneaux; Franziska Limacher-Gisler; Abdulghani Al-Saeed; Connie Luo; Ted Wu; Stephen M Twigg; Dennis K Yue; Jencia Wong Journal: Diabetes Care Date: 2013-07-11 Impact factor: 19.112
Authors: Yelba Castellon-Lopez; Kia Skrine Jeffers; O Kenrik Duru; Gerardo Moreno; Tannaz Moin; Jonathan Grotts; Carol M Mangione; Keith C Norris; Ron D Hays Journal: J Gen Intern Med Date: 2020-03-11 Impact factor: 5.128
Authors: E M Venditti; K Tan; N Chang; L Laffel; G McGinley; N Miranda; J B Tryggestad; N Walders-Abramson; P Yasuda; L Delahanty Journal: Diabetes Res Clin Pract Date: 2018-02-08 Impact factor: 5.602
Authors: Lorraine E Levitt Katz; Fida Bacha; Samuel S Gidding; Ruth S Weinstock; Laure El Ghormli; Ingrid Libman; Kristen J Nadeau; Kristin Porter; Santica Marcovina Journal: J Pediatr Date: 2018-02-02 Impact factor: 4.406
Authors: Ruth S Weinstock; Barbara H Braffett; Paul McGuigan; Mary E Larkin; Nisha B Grover; Natalie Walders-Abramson; Lori M Laffel; Christine L Chan; Nancy Chang; Beth E Schwartzman; Rose Ann Barajas; Nicole Celona-Jacobs; Morey W Haymond Journal: Diabetes Care Date: 2019-03-04 Impact factor: 19.112
Authors: Elżbieta Niechciał; Carlo L Acerini; Scott T Chiesa; Tracey Stevens; R Neil Dalton; Denis Daneman; John E Deanfield; Timothy W Jones; Farid H Mahmud; Sally M Marshall; H Andrew W Neil; David B Dunger; M Loredana Marcovecchio Journal: Diabetes Care Date: 2020-02-27 Impact factor: 19.112